Core Insights - Exact Sciences Corporation (EXAS) reported earnings per share (EPS) of 22 cents in Q2 2025, significantly better than the Zacks Consensus Estimate of a loss of 2 cents and an improvement from a loss of 9 cents in the same quarter last year [1][9] - The company’s consolidated revenues reached $811.1 million, marking a 16% increase on a reported basis and an 11% increase on a core revenue basis, exceeding the Zacks Consensus Estimate by 4.78% [2][9] Revenue Breakdown - Screening revenues, including laboratory service revenues from Cologuard tests and PreventionGenetics, increased by 18% year over year to $811 million, driven by rescreens, care gap programs, and improved commercial execution [3] - Precision Oncology revenues, which include laboratory service revenues from global Oncotype products and therapy selection products, totaled $183 million, reflecting a 9% increase from the previous year, supported by the continued international adoption of Oncotype DX [4] Margin Performance - Gross profit rose by 15.2% year over year to $562.5 million, although gross margin contracted by 49 basis points to 69.4% due to a 17.9% increase in the cost of revenues [5] - Research and development expenses decreased by 10.1% to $108.9 million, while sales and marketing expenses surged by 16.8% to $247.1 million, and general and administrative expenses increased by 17.5% to $209 million [5] Financial Update - Exact Sciences ended Q2 with cash, cash equivalents, and marketable securities totaling $858.4 million, up from $786 million at the end of Q1 [7] - Cumulative net cash provided by operating activities was $89 million, down from $107.1 million in the same period last year [7] 2025 Outlook - For the full year 2025, the company anticipates total revenues between $3.130 billion and $3.170 billion, an increase from the previous estimate of $3.070 billion to $3.120 billion [8][10] - Screening revenues are expected to be in the range of $2.440 billion to $2.470 billion, while Precision Oncology revenues are anticipated between $690 million and $700 million [10] Strategic Developments - Exact Sciences reported that a record 200,000 providers ordered Cologuard, with growth across all segments [11] - The company expanded agreements with two of its top 10 payers to make Cologuard Plus in-network and entered an exclusive license with Freenome for a blood-based colorectal cancer screening test [11] - A multiyear productivity plan has been launched to enhance operational efficiency and achieve significant cost synergies, with a target of over $150 million in annual savings by 2026 [12]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a g ...

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1] - The Relative Strength Index (RSI) is a key indicator used to identify oversold conditions, with a value below 30 indicating potential buying opportunities [1] Company Summaries - **Exact Sciences Corp (EXAS)**: Reported strong quarterly results with a focus on earlier detection. Despite positive performance, the stock fell approximately 21% over the past month, with an RSI of 22.9 and a closing price of $40.99 [8] - **Tandem Diabetes Care Inc (TNDM)**: Announced mixed second-quarter results and narrowed FY25 sales guidance below estimates. The stock declined around 27% in the last five days, with an RSI of 22.7 and a closing price of $11.23 [8] - **Outset Medical Inc (OM)**: Reported better-than-expected second-quarter results and raised FY25 sales guidance. The stock fell about 34% over the past month, with an RSI of 29.6 and a closing price of $12.80 [8]

Core Viewpoint - Exact Sciences Corp. reported a narrower EPS loss and increased revenues, indicating strong performance in its Screening and Precision Oncology segments [1][2]. Financial Performance - The company reported a second-quarter 2025 EPS loss of 1 cent, an improvement from a 9-cent loss a year ago, and better than the analyst consensus loss estimate of 19 cents [1]. - Revenues increased to $811.085 million, surpassing the consensus estimate of $774.34 million, with a 16% increase in sales on both reported and core revenue bases [1]. - Gross margin was reported at 69%, with an adjusted gross margin of 72% [2]. Product Development - Initial results from an internal colorectal cancer blood test showed sensitivities of 73% for colorectal cancer and 14% for advanced precancerous lesions at 90% specificity, with ongoing internal testing [2]. - Exact Sciences announced the acquisition of exclusive rights to Freenome's blood-based colorectal cancer screening tests, which achieved sensitivities of 81% for colorectal cancer in recent studies [5]. Guidance and Outlook - The company raised its fiscal 2025 sales guidance to $3.13 billion-$3.17 billion, compared to the previous guidance of $3.07 billion-$3.12 billion, with a Screening segment forecast of $2.44 billion-$2.47 billion [3]. - Adjusted EBITDA for 2025 is expected to be between $455 million and $475 million, an increase from the previous guidance of $425 million-$455 million [4]. Analyst Reactions - Analysts are focused on the acquisition of Freenome's rights, viewing it as a strategic move to enhance revenue potential and mitigate competitive threats [7][8]. - William Blair noted that the deal strengthens Exact Sciences' position in noninvasive colorectal cancer screening and expects improved performance in the coming years [9]. - Barclays and RBC Capital adjusted their price forecasts downward, while UBS maintained a neutral stance, reflecting mixed market sentiment [10].

Core Viewpoint - Exact Sciences (EXAS) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that an upward revision in earnings estimates can lead to increased buying pressure and higher stock prices [4][5]. - The Zacks Consensus Estimate for Exact Sciences has increased by 255.6% over the past three months, reflecting a strong positive trend in earnings outlook [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions, which positions Exact Sciences favorably for potential market-beating returns [9][10].

Group 1 - Exact Sciences reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of a loss of $0.02 per share, and showing a significant improvement from a loss of $0.09 per share a year ago, resulting in an earnings surprise of +1,200.00% [1] - The company achieved revenues of $811.09 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.78% and increasing from $699.26 million in the same quarter last year [2] - Over the last four quarters, Exact Sciences has surpassed consensus EPS estimates three times and has also topped consensus revenue estimates three times [2] Group 2 - Despite the positive earnings report, Exact Sciences shares have declined approximately 15.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $795.04 million, and for the current fiscal year, it is $0.16 on revenues of $3.1 billion [7] Group 3 - The Zacks Industry Rank indicates that the Medical - Biomedical and Genetics sector is currently in the bottom 42% of over 250 Zacks industries, which may impact the stock's performance [8] - A favorable trend in estimate revisions for Exact Sciences prior to the earnings release has resulted in a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]

Financial Data and Key Metrics Changes - Exact Sciences delivered a record 1,300,000 test results, with core revenue growth accelerating to 16% year over year and generating an all-time high of $138,000,000 in adjusted EBITDA [6][8] - Adjusted EBITDA increased by 26%, with an adjusted EBITDA margin expansion of 130 basis points [9] - GAAP net income was negative $1,000,000, including $15,000,000 in one-time costs related to operational efficiency [9] - Free cash flow was $47,000,000, bringing year-to-date free cash flow to $46,000,000, an increase of $95,000,000 compared to the same period last year [9] Business Line Data and Key Metrics Changes - Screening revenue increased by 18% to $628,000,000, driven by rescreens, CareGAP programs, and improved commercial execution [8] - Precision Oncology revenue increased by 9% to $179,000,000 on a core basis, led by Oncotype DX adoption internationally [8] Market Data and Key Metrics Changes - Cologuard brand awareness reached all-time highs, with 2,500,000,000 media impressions driven by increased digital investment [16] - The colon cancer screening landscape is shifting towards a Cologuard-first approach, as indicated by recent advocacy from the AGA work group [16] Company Strategy and Development Direction - The company is raising total revenue guidance to between $3,130,000,000 and $3,170,000, with a focus on expanding its portfolio of advanced cancer tests [11][12] - A multi-year productivity plan targeting $150,000,000 in annual savings by 2026 has been introduced, focusing on operational efficiencies and AI integration [12] - The company aims for a long-term target of 15% compounded revenue growth and more than 20% adjusted EBITDA margins by 2027 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong commercial execution and increased provider engagement [14][15] - The company is optimistic about the potential of Cologuard Plus and the new blood-based colorectal cancer screening tests, despite some setbacks in R&D [18][19] - Management emphasized the importance of maintaining strong relationships with healthcare providers and leveraging their commercial infrastructure to drive growth [22][23] Other Important Information - The company has secured favorable contracts with two of the top 10 payers, Humana and Centene, representing about 40,000,000 members [17] - The company is launching CancerGuard, a blood-based multi-cancer early detection test, addressing a significant unmet clinical need [23] Q&A Session Summary Question: Strategic fit of the Phrenome agreement - Management highlighted that the agreement adds a blood-based option to their portfolio, enhancing their leadership in noninvasive screening [30] Question: Factors contributing to strong growth - Management noted multiple tailwinds, including the launch of Cologuard Plus and improvements in commercial execution [35][38] Question: Blood test performance and FDA submission timeline - Management stated that they are confident in the performance of the Phrenome test and are awaiting FDA submission outcomes [41][80] Question: Resource allocation and strategic prioritization - Management emphasized their commitment to R&D and the potential of the multi-cancer screening market, while addressing concerns about past acquisitions [52][56] Question: Market share for blood-based testing - Management projected that blood-based testing could capture 5% to 10% of the market, depending on future guideline recommendations [91] Question: Confidence in Phrenome's clinical study rigor - Management expressed high confidence in the quality of Phrenome's study design and data, which contributed to their decision to enter the agreement [81]

Financial Data and Key Metrics Changes - Exact Sciences delivered a record 1,300,000 test results, with core revenue growth accelerating to 16% year over year, generating an all-time high of $138,000,000 in adjusted EBITDA [3][4] - Adjusted EBITDA increased by 26%, with a margin expansion of 130 basis points, driven by pricing and productivity gains [5] - GAAP net income was negative $1,000,000, including $15,000,000 in one-time costs related to operational efficiency [5] - Free cash flow reached $47,000,000, bringing year-to-date free cash flow to $46,000,000, an increase of $95,000,000 compared to the same period last year [5][6] Business Line Data and Key Metrics Changes - Screening revenue increased by 18% to $628,000,000, with growth driven by rescreens, CareGAP programs, and improved commercial execution [4] - Precision Oncology revenue grew by 9% to $179,000,000, led by international adoption of Oncotype DX [4][5] - Revenue from sublicensing Twin Strands technology contributed $7,500,000 [5] Market Data and Key Metrics Changes - Cologuard brand awareness reached all-time highs, with top-of-mind awareness matching or exceeding colonoscopy [12] - The colon cancer screening landscape is shifting towards a Cologuard-first approach, as indicated by recent advocacy from the AGA work group [12][13] - Cologuard's momentum is evident, with the company delivering its twenty millionth result, doubling from ten million in just three years [11] Company Strategy and Development Direction - The company is raising total revenue guidance for the year to between $3,130,000,000 and $3,170,000, reflecting a $55,000,000 increase at midpoint [7][8] - A multi-year productivity plan aims for $150,000,000 in annual savings by 2026, focusing on operational efficiencies and AI integration [9][10] - The company reaffirms its long-term target of 15% compounded revenue growth and over 20% adjusted EBITDA margins by 2027 [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong commercial execution and brand awareness as key drivers [11][12] - The company anticipates increased cash flow in the second half of the year as accounts receivable from Cologuard Plus claims are paid [6] - Management acknowledged challenges in blood-based colorectal cancer screening but remains optimistic about future developments and the potential of the Phrenome acquisition [14][15] Other Important Information - The company has secured Medicare coverage for OncoDetect, enhancing its precision oncology offerings [3][21] - The launch of CancerGuard, a blood-based multi-cancer early detection test, is set for next month, targeting a $25,000,000,000 addressable market [19][20] Q&A Session Summary Question: Strategic fit of the Phrenome agreement - Management highlighted that the agreement adds a blood-based option to their portfolio, complementing existing tests and enhancing market leadership [26][27] Question: Factors contributing to strong growth - Management attributed growth to the successful launch of Cologuard Plus and improvements in commercial execution, with strong performance across all business segments [32][34] Question: Blood test performance and FDA submission timeline - Management stated that the Phrenome test showed promising sensitivity and specificity, with the final module submitted to the FDA, but did not provide a specific timeline for approval [39][40] Question: Concerns about resource allocation and strategic prioritization - Management disagreed with the notion that past acquisitions were unsuccessful, emphasizing the impact of Cologuard and the potential of the blood-based screening market [49][50] Question: Market share expectations for blood-based testing - Management projected that blood-based testing could capture 5% to 10% of the market, depending on future guideline recommendations [88][90]

[Part I - Financial Information](index=3&type=section&id=Part%20I%20-%20Financial%20Information) This section presents the company's financial statements, management's discussion and analysis, market risk disclosures, and internal controls [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) The financial statements for the period ended June 30, 2025, show a 16.0% year-over-year revenue increase to $811.1 million for the second quarter, driven by growth in both Screening and Precision Oncology, with a significantly narrowed net loss [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets were $5.80 billion, a slight decrease from year-end 2024, while total liabilities decreased to $3.33 billion, largely due to convertible notes settlement Condensed Consolidated Balance Sheets (in thousands) | Balance Sheet Item | June 30, 2025 ($ thousands) | December 31, 2024 ($ thousands) | | :--- | :--- | :--- | | **Total Current Assets** | 1,507,859 | 1,571,423 | | Cash and cash equivalents | 657,099 | 600,889 | | Marketable securities | 201,336 | 437,137 | | **Total Assets** | **5,797,365** | **5,928,139** | | **Total Current Liabilities** | 521,933 | 732,187 | | Convertible notes, net, current portion | — | 249,153 | | **Total Liabilities** | **3,327,951** | **3,525,890** | | **Total Stockholders' Equity** | **2,469,414** | **2,402,249** | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q2 2025, revenue grew 16.0% to $811.1 million, with a significantly reduced net loss of $1.2 million, while six-month revenue increased 13.5% to $1.52 billion Condensed Consolidated Statements of Operations - Q2 (in thousands, except EPS) | Metric (in thousands, except EPS) | Q2 2025 | Q2 2024 | YoY Change | | :--- | :--- | :--- | :--- | | **Revenue** | $811,085 | $699,264 | +16.0% | | **Gross Profit** | $562,453 | $488,316 | +15.2% | | **Loss from Operations** | $(2,148) | $(26,257) | +91.8% | | **Net Loss** | $(1,185) | $(15,808) | +92.5% | | **Net Loss Per Share** | $(0.01) | $(0.09) | +88.9% | Condensed Consolidated Statements of Operations - H1 (in thousands, except EPS) | Metric (in thousands, except EPS) | H1 2025 | H1 2024 | YoY Change | | :--- | :--- | :--- | :--- | | **Revenue** | $1,517,870 | $1,336,788 | +13.5% | | **Gross Profit** | $1,063,000 | $934,639 | +13.7% | | **Loss from Operations** | $(98,158) | $(132,949) | +26.2% | | **Net Loss** | $(102,400) | $(126,036) | +18.8% | | **Net Loss Per Share** | $(0.55) | $(0.69) | +20.3% | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the first six months of 2025, net cash provided by operating activities significantly improved to $119.8 million, with cash and cash equivalents increasing by $50.5 million Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activity (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $119,826 | $24,754 | | **Net cash provided by (used in) investing activities** | $190,458 | $(318,567) | | **Net cash provided by (used in) financing activities** | $(260,685) | $221,601 | | **Net increase (decrease) in cash** | $50,463 | $(73,658) | - The primary use of cash in financing activities was a **$249.2 million** payment for the settlement of convertible notes that matured in January 2025[23](index=23&type=chunk)[98](index=98&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting policies, revenue recognition, debt, and collaborations, highlighting strong Screening revenue growth, convertible notes settlement, and a new collaboration with Freenome Revenue by Source (in thousands) | Revenue Source (in thousands) | Q2 2025 | Q2 2024 | YoY Change | | :--- | :--- | :--- | :--- | | **Screening** | $628,481 | $531,606 | +18.2% | | **Precision Oncology** | $182,604 | $167,658 | +8.9% | | **Total Revenue** | **$811,085** | **$699,264** | **+16.0%** | - In January 2025, the company settled its 2025 Convertible Notes with a cash payment of **$250.4 million** upon maturity[98](index=98&type=chunk) - On July 22, 2025, the company initiated a restructuring plan expected to result in approximately **$30 million** in costs through 2026, primarily for employee termination and consulting fees[167](index=167&type=chunk) - On August 4, 2025, the company entered into a collaboration and license agreement with Freenome, involving a **$75.0 million** upfront payment and up to **$700.0 million** in potential milestone payments for developing and commercializing blood-based colorectal cancer screening tests[169](index=169&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=35&type=section&id=Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes Q2 2025 revenue growth to increased Cologuard and Oncotype DX test volumes, with new product launches and a multi-year productivity plan targeting over $150 million in annual savings by 2026 - Key milestones in Q2 2025 include delivering over **1.3 million** test results, obtaining Medicare reimbursement for the Oncodetect MRD test, and entering an exclusive license agreement with Freenome for blood-based CRC screening[177](index=177&type=chunk) - The company launched its next-generation Cologuard Plus test in late March 2025 and its Oncodetect MRD test in April 2025, with plans to launch its Cancerguard multi-cancer early detection test in Q3 2025[182](index=182&type=chunk) - A multi-year productivity plan is expected to deliver over **$150 million** in annual savings by 2026, primarily from general and administrative efficiencies, with expected restructuring costs of **$105 million to $120 million** through 2026[189](index=189&type=chunk) [Results of Operations](index=39&type=section&id=Results%20of%20Operations) Screening revenue grew 18.2% in Q2 2025 due to higher Cologuard test volume, while Precision Oncology revenue increased 8.9% driven by Oncotype DX adoption and sublicense revenue, with R&D expenses decreasing due to non-recurring items - The increase in Screening revenue was primarily due to a higher number of completed Cologuard tests, driven by increases in rescreen rates, care gap programs, and growth in new ordering providers[196](index=196&type=chunk) - Precision Oncology revenue growth was driven by an increase in Oncotype DX breast cancer tests, particularly in Japan, and recognition of **$7.5 million** in sublicense revenue[197](index=197&type=chunk) - Research and development expenses decreased by **10.1% YoY** for the quarter, primarily because Q2 2024 included a **$25.8 million** expense for a license agreement termination[202](index=202&type=chunk) [Liquidity and Capital Resources](index=43&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company held $657.1 million in cash and cash equivalents and $201.3 million in marketable securities, with a new undrawn $500.0 million revolving credit agreement, sufficient to fund operations for at least the next 12 months - The company had **$657.1 million** in cash and cash equivalents and **$201.3 million** in marketable securities as of June 30, 2025[214](index=214&type=chunk) - In January 2025, the company entered into a new **$500.0 million** senior secured revolving credit agreement, which was undrawn as of June 30, 2025[212](index=212&type=chunk) - A material cash requirement was met in January 2025 with a **$250.4 million** payment to settle the 2025 Notes upon maturity[221](index=221&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=45&type=section&id=Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk exposures relate to interest rate risk on its cash, cash equivalents, and marketable securities, and foreign currency risk from its international operations, managed through conservative investment policies and forward contracts - Market risk is primarily confined to cash, cash equivalents, and marketable securities, which are invested in high-quality, investment-grade instruments[227](index=227&type=chunk) - The company uses foreign currency forward contracts to mitigate exchange rate risk, with open contracts having a notional value of **$50.8 million** as of June 30, 2025[231](index=231&type=chunk) [Item 4. Controls and Procedures](index=46&type=section&id=Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2025, with no significant changes in internal control over financial reporting during the quarter - The principal executive officer and principal financial officer concluded that as of June 30, 2025, the company's disclosure controls and procedures were effective[232](index=232&type=chunk) - No significant changes in internal control over financial reporting occurred during the quarter ended June 30, 2025[233](index=233&type=chunk) [Part II - Other Information](index=47&type=section&id=Part%20II%20-%20Other%20Information) This section covers legal proceedings, risk factors, and other significant corporate events [Item 1. Legal Proceedings](index=47&type=section&id=Legal%20Proceedings) The company is involved in ongoing intellectual property litigation with Geneoscopy, Inc., concerning patent infringement and false advertising, with recent PTAB decisions impacting patent validity - The company is in a legal dispute with Geneoscopy, Inc. over alleged patent infringement of the '781 and '746 patents and violations of the Lanham Act[153](index=153&type=chunk) - On July 9, 2025, the Patent Trial and Appeals Board (PTAB) found all claims of the '781 Patent unpatentable, with a notice of appeal potentially filed by September 10, 2025[154](index=154&type=chunk) [Item 1A. Risk Factors](index=47&type=page&id=Item%201A.%20Risk%20Factors) The company faces key risks including reliance on strategic collaborations, dependence on single-source suppliers, and uncertainties from potential healthcare reforms and evolving reimbursement policies - The company relies on strategic collaborations, such as with Mayo and the new Freenome agreement, and faces risks if these agreements are not maintained or if anticipated benefits are not realized[237](index=237&type=chunk) - Dependence on single-source suppliers like Phillips-Medisize (Cologuard kits), Illumina (sequencing platforms), and Hamilton (lab equipment) poses a significant operational risk[240](index=240&type=chunk)[241](index=241&type=chunk) - Uncertainty related to healthcare reform, including legal challenges to the ACA and changes in Medicare reimbursement under PAMA, could adversely affect coverage and profitability[246](index=246&type=chunk)[247](index=247&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=50&type=section&id=Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) Not applicable [Item 3. Defaults Upon Senior Securities](index=50&type=section&id=Defaults%20Upon%20Senior%20Securities) Not applicable [Item 4. Mine Safety Disclosures](index=50&type=section&id=Mine%20Safety%20Disclosures) Not applicable [Item 5. Other Information](index=50&type=section&id=Other%20Information) This section details significant corporate events including a collaboration with Freenome, amendments to executive employment agreements, and a Board of Directors resignation - On August 4, 2025, the company entered into a Collaboration and License Agreement with Freenome to develop and commercialize blood-based CRC screening products, which includes a **$75 million** upfront payment and potential milestones[255](index=255&type=chunk) - On August 5, 2025, the company amended the employment agreements for executives Brian Baranick, Aaron Bloomer, Sarah Condella, and Jake Orville, modifying the acceleration of equity vesting upon certain termination events[259](index=259&type=chunk) - Daniel Levangie resigned from the Board of Directors on August 5, 2025, due to his retirement[261](index=261&type=chunk) [Item 6. Exhibits](index=52&type=section&id=Exhibits) This section lists the documents filed as part of the Form 10-Q, including amendments to employment agreements, certifications, and iXBRL data files

Financial Performance - Q2 2025 - Total revenue reached $811 million in Q2 2025, a 16% year-over-year increase[5] - Adjusted EBITDA for Q2 2025 was $138 million, up 26% year-over-year[5] - Core revenue also grew by 16% in Q2 2025[7] - Screening revenue increased by 18% from $532 million in Q2 2024 to $628 million in Q2 2025[8] - Precision Oncology core revenue increased by 9% from $165 million in Q2 2024 to $179 million in Q2 2025[8] Profitability and Cash Flow - Adjusted EBITDA margin improved to 17% in Q2 2025, an increase of 130 basis points[11] - Free cash flow was $46 million[11] Updated 2025 Guidance - Total revenue guidance updated to $3.13 billion - $3.17 billion, an increase of $55 million at the midpoint[13] - Screening revenue guidance updated to $2.44 billion - $2.47 billion, an increase of $48 million at the midpoint[13] - Adjusted EBITDA guidance updated to $455 million - $475 million, an increase of $25 million at the midpoint[13] Cost Savings Initiatives - A multi-year productivity program aims for $150 million in annual run-rate cost savings by 2026[16, 17]